new space

Houston-area space tech startup gets upgraded control center

A Houston-based company that's on a mission to the moon has a new control center. Photo via Jesus Motto/Savills

A space tech startup based in Clear Lake, just outside of Houston, has a new office that's going to help them take their technology out of this world.

Intuitive Machines, an engineering firm specializing in automation and aerospace, has upgraded its Houston-area control center. The company has moved into a 22,300-square-foot space on the sixth floor of a building located at 3700 Bay Area Road. The lease was executed last fall. London-based Savills had a Houston team to represent the tenant and oversee project management of the buildout.

"I was proud to work on the build-out for Intuitive Machines during such an exciting time in its history," says Savills associate director, David Finklea, in a news release. "As Intuitive is a leader in the aerospace space field, we created an environment that is far from the industry standard and complements its innovative endeavors. The design is bright and contemporary, with a relaxing and airy feel that imitates the illusion of being in space."

Currently, Intuitive Machines is working on NASA's Artemis Program and has been granted $77 million from the organization to launch a flight to the moon next year. In light of this project, Intuitive Machines needed a larger, optimized space to support its growing team.

Finklea and Derrell Curry, executive vice president at Savills, teamed up with architecture firm CDI Douglass Pye Inc. on the project that took elements from the company's former first-floor office and created a new design aesthetic that "evoked the neutral colors of the lunar landscape," according to the release.

"Despite the current COVID-19 pandemic and delays caused as a result, we were able to complete the space within six months through close coordination with Intuitive Machines, CDI Douglass Pye, and the landlord," Finklea says in the release. "Everyone came together to ensure the new headquarters was delivered promptly for Intuitive Machines to prepare for its historic mission that further solidifies the future of privatized space travel."

The unique control center is circular, which optimizes collaboration, and equipped with a large curved monitor. The office is also hooked up to emergency backup power — something the team needs as it continues on its mission to the moon.

"I couldn't be more pleased with Derrell and David and the team they put together to create our new headquarters. Everyone demonstrated a high level of professionalism and attention to detail that produced a workplace that truly represents Intuitive Machines as an innovative lunar space systems company," says Steve Altemus, president and CEO of Intuitive Machines, in the release. "Thank you to Savills, CDI Douglass Pye, and Byrd Construction for delivering an exceptional space that allows us to conduct our mission to the moon from our new control center right here in Houston!"

Intuitive Machines moved into a new space. Photo via Jesus Motto/Savills

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted